136 related articles for article (PubMed ID: 19304880)
1. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting.
Howell J; Smeets J; Drenth HJ; Gill D
J Oncol Pharm Pract; 2009 Dec; 15(4):223-31. PubMed ID: 19304880
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study.
Boccia RV; Gordan LN; Clark G; Howell JD; Grunberg SM;
Support Care Cancer; 2011 Oct; 19(10):1609-17. PubMed ID: 20835873
[TBL] [Abstract][Full Text] [Related]
3. Transdermal granisetron: a guide to its use in preventing nausea and vomiting induced by chemotherapy.
Keating GM; Duggan ST; Curran MP
CNS Drugs; 2012 Sep; 26(9):787-90. PubMed ID: 22834568
[TBL] [Abstract][Full Text] [Related]
4. Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study.
Yang LQ; Sun XC; Qin SK; Chen YX; Zhang HL; Cheng Y; Chen ZD; Shi JH; Wu Q; Bai YX; Han BH; Liu W; Ouyang XN; Liu JW; Zhang ZH; Li YQ; Xu JM; Yu SY
Chin Clin Oncol; 2016 Dec; 5(6):79. PubMed ID: 28061543
[TBL] [Abstract][Full Text] [Related]
5. A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation.
Armbruster SD; Fellman BM; Jhingran A; Eifel PJ; Klopp AH; Coleman RL; Ramondetta LM; Frumovitz M
Support Care Cancer; 2021 Jan; 29(1):213-222. PubMed ID: 32338316
[TBL] [Abstract][Full Text] [Related]
6. The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy.
Carmichael J; Harris AL
Cancer Chemother Pharmacol; 2004 Feb; 53(2):123-8. PubMed ID: 14634790
[TBL] [Abstract][Full Text] [Related]
7. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of transdermal granisetron in women with nausea and vomiting of pregnancy.
Caritis S; Zhao Y; Chen HJ; Venkataramanan R
Am J Obstet Gynecol; 2016 Jul; 215(1):93.e1-4. PubMed ID: 26812081
[TBL] [Abstract][Full Text] [Related]
9. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
Ettinger DS; Eisenberg PD; Fitts D; Friedman C; Wilson-Lynch K; Yocom K
Cancer; 1996 Jul; 78(1):144-51. PubMed ID: 8646710
[TBL] [Abstract][Full Text] [Related]
10. A granisetron patch (sancuso).
Med Lett Drugs Ther; 2008 Dec 15-29; 50(1301-1302):103-4; quiz p 2 following 104. PubMed ID: 19078867
[No Abstract] [Full Text] [Related]
11. Granisetron transdermal system: a new option to help prevent chemotherapy-induced nausea and vomiting.
Schulmeister L
Clin J Oncol Nurs; 2009 Dec; 13(6):711-4. PubMed ID: 19948469
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting.
Nakade S; Ohno T; Kitagawa J; Hashimoto Y; Katayama M; Awata H; Kodama Y; Miyata Y
Cancer Chemother Pharmacol; 2008 Dec; 63(1):75-83. PubMed ID: 18317761
[TBL] [Abstract][Full Text] [Related]
13. Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy.
Gurpide A; Sadaba B; Martin-Algarra S; Azanza JR; Lopez-Picazo JM; Campanero MA; Cabello JP; Gil-Aldea I; de la Cruz S; Fernandez Gallego V; Reyna C; Olier Garate C; Blanco-Prieto MJ; Ceballos J; Garcia-Foncillas J; Perez-Gracia JL
Oncologist; 2007 Sep; 12(9):1151-5. PubMed ID: 17914085
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Addelman M; Erlichman C; Fine S; Warr D; Murray C
J Clin Oncol; 1990 Feb; 8(2):337-41. PubMed ID: 2153767
[TBL] [Abstract][Full Text] [Related]
15. Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting.
Jordan K; Grothey A; Kegel T; Fibich C; Schöbert C
Onkologie; 2005 Feb; 28(2):88-92. PubMed ID: 15662112
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
Burris H; Hesketh P; Cohn J; Moriconi W; Ryan T; Friedman C; Fitts D
Cancer J Sci Am; 1996; 2(2):85-90. PubMed ID: 9166505
[TBL] [Abstract][Full Text] [Related]
17. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects.
Blum RA; Majumdar A; McCrea J; Busillo J; Orlowski LH; Panebianco D; Hesney M; Petty KJ; Goldberg MR; Murphy MG; Gottesdiener KM; Hustad CM; Lates C; Kraft WK; Van Buren S; Waldman SA; Greenberg HE
Clin Ther; 2003 May; 25(5):1407-19. PubMed ID: 12867217
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic potential of Granisetron (Kitryl) for the prevention of nausea and vomiting induced by cytostatic drugs].
Gershanovich ML; Beresneva IA
Vopr Onkol; 1998; 44(2):225-8. PubMed ID: 9615833
[TBL] [Abstract][Full Text] [Related]
20. Management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day highly or moderately emetogenic chemotherapy: role of transdermal granisetron.
Coluzzi F; Mattia C
Future Oncol; 2016 Aug; 12(16):1865-76. PubMed ID: 27184113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
